FULC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
Cost of Revenue
0
0
0
0
0
Gross Profit
Operating Expenses
29.3M
+32.1%
22.2M
-2.2%
22.7M
+3.8%
21.9M
+10.3%
19.8M
R&D
12.4M
-11.6%
14.1M
-8.6%
15.4M
+7.8%
14.3M
+10.1%
13.0M
SG&A
7.5M
-7.9%
8.1M
+11.3%
7.3M
-3.8%
7.6M
+10.7%
6.8M
Operating Income
-29310000
-32.1%
-22186000
+2.2%
-22693000
-3.8%
-21858000
-10.3%
-19815000
EBITDA
-19690000
+9.9%
-21848000
+2.2%
-22346000
-3.9%
-21512000
-10.5%
-19471000
Net Income
-26179000
-38.6%
-18891000
+7.1%
-20334000
-3.8%
-19595000
-13.3%
-17296000
EPS (Basic)
$-0.34
-36.0%
$-0.25
+19.4%
$-0.31
+0.0%
$-0.31
-10.7%
$-0.28
EPS (Diluted)
$-0.34
-36.0%
$-0.25
+19.4%
$-0.31
+0.0%
$-0.31
-10.7%
$-0.28
Shares (Diluted)
76.3M
+0.1%
76.2M
+15.8%
65.8M
+5.1%
62.6M
+0.1%
62.5M
Fulcrum Therapeutics (FULC) — Financials